Pharma Focus Asia

Fujifilm Plans to Open Large Scale Cell Culture Production Site in USA

Introduction:

FUJIFILM Corporation plans to open a new large scale cell culture manufacturing site for biopharmaceuticals with an investment of more than US$ 2 billion. The new site will be located adjacent to the existing site in USA.

Features:

The new production facility will advance the growth of its biopharmaceutical Contract Development and Manufacturing business (CDMO). In addition, the investment made in this new site helps in fulfilling the unmet medical needs with the manufacturing of new drugs.

The new production facility will be situated adjacent to the existing site and offers commercial scale automated fill-finish and assembly,  packaging and labelling services other than drug manufacturing substances.

The facility offers 8 x 20,000L bioreactors to expand with the addition of 24 x 20,000L bioreactorsfor large-scale cell culture manufacturing.

The production facility is expected to start its operation in the spring of 2025.

Specifications:

NameFUJIFILM Corporation
TypeNew Construction
BudgetUS$2 billion
Year2025
magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024